OPM announces equity financing of up to 5 million euros
Dijon, France, April 17, 2025, at 6:00 pm CEST - Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the completion of an equity financing line of up to 5 million euros, in order to complete all financing options in a context of currently very high stock market uncertainty.